Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KA2237 in Patients With B Cell Lymphoma
NCT02679196Phase 1Completed
- Sponsor
- Karus Therapeutics
- Start
- Jul 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of conpelisib in B cell lymphoma, sponsored by Karus Therapeutics. Primary endpoint: Dose Limiting Toxicity at Day 28. Started Jul 2016; status: completed.
02
Drugs
conpelisib
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02679196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679196.